6 January 2014
EMA/PRAC/4877/2014
Pharmacovigilance Risk Assessment Committee (PRAC)

Pharmacovigilance Risk Assessment Committee (PRAC)

Draft agenda for the meeting on 6-9 January 2014

Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures
(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0

Signals assessment and prioritisation
(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks.
The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.
The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)
(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.
RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)
(Item 6 of the PRAC agenda)

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7051
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation.
PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)
(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections
(Item 8 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

Chair: June Raine – Vice-Chair: Almath Spooner

6 January 2014, 14:30 – 19:00, room 3/A

7 January 2014, 08:30 – 19:00, room 3/A

8 January 2014, 08:30– 19:00, room 3/A

9 January 2014, 08:30 – 16:00, room 3/A

Organisational, regulatory and methodological matters (ORGAM)

22 January 2014, 10:00-12:00, room 2/E, via teleconference

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

1.2. Adoption of agenda of the meeting of 6-9 January 2014

Status: *for adoption*

Document: PRAC Agenda Rev.3 due for publication on 6 January 2014

1.3. Minutes of the previous PRAC meeting on 2-5 December 2013

Status: *for adoption*

Document: PRAC Final Minutes due for publication on 17 January 2014

2. EU Referral Procedures for Safety Reasons: Urgent EU Procedures

2.1. Newly triggered procedures

None

2.2. Ongoing Procedures

None

2.3. Procedures for finalisation

None

2.4. Planned public hearings

None

3. EU Referral Procedures for Safety Reasons: Other EU Referral Procedures

3.1. Newly triggered Procedures

None

3.2. Ongoing Procedures

3.2.1. Agents acting on the renin-angiotensin system (CAP, NAP):
angiotensin receptor blockers (**ARBs**), **angiotensin converting enzyme inhibitors** (**ACEi**), **direct renin inhibitors** (**aliskiren**)

- Review of the risks of dual blockade of the renin angiotensin system through concomitant use of ARBs, ACEi or aliskiren-containing medicines following notification by Italy of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

Status: *for discussion*

Regulatory details:

PRAC Rapporteur: Carmela Macchiarulo (IT)
PRAC Co-Rapporteurs: Margarida Guimarães (PT), Valerie Strassmann (DE), Tatiana Magálová (SK), Dolores Montero Corominas (ES), Almath Spooner (IE), Menno van der Elst (NL), Julie Williams (UK), Qun-Ying Yue (SE)

3.2.2. **Domperidone** (NAP)

- Review of the benefit-risk balance following notification by Belgium of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

Status*: for discussion*

Regulatory details:

PRAC Rapporteur: Isabelle Robine (FR)
PRAC Co-Rapporteur: Jean-Michel Dogné (BE)

3.3. Procedures for finalisation

3.3.1. **Strontium ranelate – OSSEOR** (CAP), **PROTELOS** (CAP)

- Review of the benefit-risk balance following notification by the European Commission of a referral under Article 20(8) of Regulation (EC) No 726/2004, following procedural steps of Article 31 of Directive 2001/83/EC, based on pharmacovigilance data

Status: *for discussion and adoption of recommendation to CHMP*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)
PRAC Co-Rapporteur: Harald Herkner (AT)

3.4. Article 5(3) of Regulation (EC) No 726/2004 as amended: PRAC advice on CHMP request

None

4. Signals assessment and prioritisation[1]

4.1. New signals detected from EU spontaneous reporting systems

4.1.1. **Abatacept - ORENCIA** (CAP)

- Signal of angioedema

Status: *for discussion*

Regulatory details:

PRAC Rapporteur: Kirsti Villikka (FI)

[1] Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required.

4.1.2. Duloxetine - **ARICLAIM** (CAP), **CYMBALTA** (CAP), **XERISTAR** (CAP), **YENTREVE** (CAP)

- Signal of vasculitis

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

4.1.3. Fluticasone furoate - **AVAMYS** (CAP)

- Signal of oral and upper respiratory fungal infection

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Adam Przybylkowski (PL)

4.1.4. **Leuprorelin** (NAP)

- Signal of wrong technique in drug usage process

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: *to be appointed*

4.1.5. Pazopanib – **VOTRIENT** (CAP)

- Signal of retinal detachment and retinal tear

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Doris Stenver (DK)

4.2. New signals detected from other sources

4.2.1. Tenofovir disoproxil fumarate – **VIREAD** (CAP); **Diclofenac** (NAP)

- Signal of acute kidney injury caused by co-administration of tenofovir disoproxil fumarate and diclofenac - publication from Bickel et al, HIV Medicine 2013

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

4.3. Signals follow-up and prioritisation

4.3.1. Dexmedetomidine – **DEXDOR** (CAP)

- Signal of infantile apnoeic attack

***Status**: for discussion*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

4.3.2. Orlistat – ALLI (CAP), **XENICAL** (CAP)
Atazanavir - REYATAZ (CAP); **darunavir - PREZISTA** (CAP); **efavirenz – STOCRIN** (CAP), **SUSTIVA** (CAP); **emtricitabine, efavirenz, tenofovir** – **ATRIPLA** (CAP); **emtricitabine, tenofovir - TRUVADA** (CAP); **lopinavir, ritonavir – KALETRA** (CAP)

- Signal of pharmacokinetic drug interaction (at absorption) with highly active antiretroviral therapy (HAART) leading to loss of HAART efficacy

***Status**: for discussion*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

4.3.3. Tapentadol (NAP)

- Signal of suicidal ideation

***Status:** for discussion*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

4.3.4. Triamcinolone acetonide (NAP)

- Signal of postmenopausal haemorrhage

***Status**: for discussion*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

5. Risk Management Plans

5.1. Medicines in the pre-authorisation phase

5.1.1. Albiglutide

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

***Status:** for discussion and agreement of advice to CHMP*

5.1.2. Etarfolatide

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

***Status:** for discussion and agreement of advice to CHMP*

5.1.3. Folic acid

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.4. Hepatitis B, surface antigen vaccine

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.5. Ketorolac trometamol, phenylephrine

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.6. Lurasidone

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.7. Naloxegol

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.8. Olaparib

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.9. Ramucirumab

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.10. Riociguat

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.11. Siltuximab

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

5.1.12. Simeprevir

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

5.1.13. Umeclidinium bromide

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.14. Umeclidinium bromide, vilanterol

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.15. Vintafolide

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.16. Zoledronic acid

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.2. Medicines already authorised

RMP in the context of a PSUR procedure

See Cabazitaxel (JEVTANA) under 6.1.7. ; Galsulfase (NAGLAZYME) under 6.1.13. ; Paliperidone (INVEGA, XEPLION) under 6.1.23. ; Pegaptanib (MACUGEN) under 6.1.24. ; Pertuzumab (PERJETA) under 6.1.25. ; Roflumilast (DAXAS, DALIRESP, LIBERTEK) under 6.1.27. ; Ticagrelor (BRLILIQUE) under 6.1.29.

RMP in the context of a variation

5.2.1. Cabazitaxel – JEVTANA (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

5.2.2. Capecitabine – XELODA (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

5.2.3. Catridecacog – NOVOTHIRTEEN (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

5.2.4. Dabigatran – PRADAXA (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Doris Stenver (DK)

5.2.5. Dabigatran – PRADAXA (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Doris Stenver (DK)

5.2.6. Dabrafenib – TAFINLAR (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

5.2.7. Darbepoetin alfa – ARANESP (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Valerie Strassmann (DE)

5.2.8. Emtricitabine, efavirenz, tenofovir – ATRIPLA (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

5.2.9. Eslicarbazepine – ZEBINIX (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

5.2.10. Filgrastim – GRASTOFIL (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

5.2.11. Insulin degludec – TRESIBA (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

5.2.12. Ivacaftor – KALYDECO (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Miguel-Angel Macia (ES)

5.2.13. Ivacaftor – KALYDECO (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Miguel-Angel Macia (ES)

5.2.14. Ivacaftor – KALYDECO (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Miguel-Angel Macia (ES)

5.2.15. Measles, mumps, rubella and varicella vaccine – PROQUAD (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

5.2.16. Meningococcal group a, c, w135 and y conjugate vaccine – MENVEO (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

5.2.17. Ofatumumab – ARZERRA (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Doris Stenver (DK)

5.2.18. Omalizumab – XOLAIR (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

5.2.19. Posaconazole – NOXAFIL (CAP)

- Evaluation of an RMP in the context of a variation, line extension

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julia Dunne (UK)

5.2.20. Ranibizumab – LUCENTIS (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

5.2.21. Rituximab – MABTHERA (CAP)

- Evaluation of an RMP in the context of a variation, line extension

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Doris Stenver (DK)

5.2.22. Sorafenib – NEXAVAR (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

5.2.23. Ustekinumab – STELARA (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

RMP in the context of a renewal of the marketing authorisation, conditional renewal or annual reassessment

See Abacavir (ZIAGEN) under 8.1.1. ;Lapatinib (TYVERB) under 8.1.6. ; Mecasermin (INCRELEX) under 8.1.7. ; Tocofersolan (VEDROP) under 8.1.10.

RMP in the context of a stand-alone RMP procedure

5.2.24. Eptotermin alfa – OSIGRAFT (CAP)

- Evaluation of an RMP in the context of a stand-alone RMP procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Kirsti Villikka (FI)

6. Periodic Safety Update Reports (PSURs)

6.1. Evaluation of PSUR procedures[2]

6.1.1. 5-aminolevulinic acid – AMELUZ (CAP), NAP

- Evaluation of a PSUSA[3] procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

6.1.2. Aflibercept – EYLEA (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

6.1.3. Ambrisentan – VOLIBRIS (CAP)

- Evaluation of a PSUR procedure

[2] Where a regulatory action is recommended (variation, suspension or revocation of the terms of Marketing Authorisation(s)), the assessment report and PRAC recommendation are transmitted to the CHMP for adoption of an opinion. Where PRAC recommends the maintenance of the terms of the marketing authorisation(s), the procedure finishes at the PRAC level.
[3] PSUR single assessment, referring to CAP, NAP

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

6.1.4. Belatacept – NULOJIX (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

6.1.5. Bromelain enriched proteolytic enzymes preparation from ananas comosus – NEXOBRID (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

6.1.6. C1 inhibitor, human – CINRYZE (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

6.1.7. Cabazitaxel – JEVTANA (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

6.1.8. Caffeine – PEYONA (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Harald Herkner (AT)

6.1.9. Canakinumab – ILARIS (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

6.1.10. Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and haemophilus influenzae type b conjugate vaccine (adsorbed) – HEXACIMA (CAP), **HEXAXIM** (Art 58), **HEXYON** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

6.1.11. Ferumoxytol – RIENSO (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

6.1.12. Fidaxomicin – DIFICLIR (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

6.1.13. Galsulfase – NAGLAZYME (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julia Dunne (UK)

6.1.14. Human hepatitis B immunoglobulin – ZUTECTRA (CAP), NAP

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

6.1.15. Human normal immunoglobulin – FLEBOGAMMA DIF (CAP), **HIZENTRA** (CAP), **KIOVIG** (CAP), **PRIVIGEN** (CAP), NAP

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

6.1.16. Human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) – **GARDASIL** (CAP), **SILGARD** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

6.1.17. Icatibant – **FIRAZYR** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

6.1.18. Influenza vaccine (live attenuated, nasal) – **FLUENZ** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

6.1.19. Liraglutide – **VICTOZA** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

6.1.20. Nepafenac – **NEVANAC** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

6.1.21. Nitric oxide – **INOMAX** (CAP), NAP

- Evaluation of a PSUSA procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

6.1.22. Omalizumab – XOLAIR (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

6.1.23. Paliperidone – INVEGA (CAP), XEPLION (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

6.1.24. Pegaptanib – MACUGEN (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Jean-Michel Dogné (BE)

6.1.25. Pertuzumab – PERJETA (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Doris Stenver (DK)

6.1.26. Ranibizumab – LUCENTIS (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

6.1.27. Roflumilast – DALIRESP (CAP), DAXAS (CAP), LIBERTEK (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Miguel-Angel Macia (ES)

6.1.28. Sildenafil – **REVATIO** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

6.1.29. Ticagrelor – **BRILIQUE** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

6.1.30. Tobramycin – **TOBI PODHALER** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

6.2. Follow-up to PSUR procedures[4]

6.2.1. Aclidinium bromide – **BRETARIS GENUAIR** (CAP), **EKLIRA GENUAIR** (CAP)

- Evaluation of a follow-up to a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

6.2.2. Anidulafungin – **ECALTA** (CAP)

- Evaluation of a follow-up to a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

6.2.3. Caspofungin – **CANCIDAS** (CAP)

- Evaluation of a follow-up to a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Jean-Michel Dogné (BE)

[4] Follow up as per the conclusions of the previous PSUR procedure, assessed outside next PSUR procedure

6.2.4. Infliximab – REMICADE (CAP)

- Evaluation of a follow-up to a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

6.2.5. Sugammadex – BRIDION (CAP)

- Evaluation of a follow-up to a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Kirsti Villikka (FI)

7. Post-authorisation Safety Studies (PASS)

7.1. Protocols of PASS imposed in the marketing authorisation(s)[5]

7.1.1. Deferasirox – EXJADE (CAP)

- Evaluation of an imposed PASS protocol

Status: *for discussion and agreement of PRAC letter of endorsement/objection/notification*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

7.1.2. Defibrotide – DEFITELIO (CAP)

- Evaluation of an imposed PASS protocol

Status: *for discussion and agreement of PRAC letter of endorsement/objection/notification*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

7.1.3. Imatinib – GLIVEC (CAP)

- Evaluation of an imposed PASS protocol

Status: *for discussion and agreement of PRAC letter of endorsement/objection/notification*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

7.1.4. Lenalidomide – REVLIMID (CAP)

- Evaluation of an imposed PASS protocol

[5] In accordance with Article 107n of Directive 2001/83/EC

Status: *for discussion and agreement of PRAC letter of endorsement/objection/notification*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

7.1.5. **Levonorgestrel** (NAP)

- Evaluation of an imposed PASS protocol

Status: *for discussion and agreement of PRAC letter of endorsement/objection/notification*

Regulatory details:
Lead member: Ulla Wändel Liminga (SE)

7.1.6. **Nomegestrol, estradiol – IOA** (CAP), **ZOELY** (CAP)

- Evaluation of an imposed PASS protocol

Status: *for discussion and agreement of PRAC letter of endorsement/objection/notification*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

7.1.7. **Tigecycline – TYGACIL** (CAP)

- Evaluation of an imposed PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Miguel-Angel Macia (ES)

7.2. Protocols of PASS non-imposed in the marketing authorisation(s)[6]

7.2.1. **Bivalirudin – ANGIOX** (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

7.2.2. **Eltrombopag – REVOLADE** (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

7.2.3. **Eltrombopag – REVOLADE** (CAP)

- Evaluation of a PASS protocol

[6] In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

7.2.4. Eltrombopag – REVOLADE (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

7.2.5. Eltrombopag – REVOLADE (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

7.2.6. Eltrombopag – REVOLADE (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

7.2.7. Golimumab – SIMPONI (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

7.2.8. Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) – OPTAFLU (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

7.2.9. Voriconazole – VFEND (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

7.3. Results of PASS imposed in the marketing authorisation(s)[7]

None

7.4. Results of PASS non-imposed in the marketing authorisation(s)[8]

7.4.1. Lomitapide – **LOJUXTA** (CAP)

- Evaluation of PASS results

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

7.4.2. Maraviroc – **CELSENTRI** (CAP)

- Evaluation of PASS results

Status: *for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

7.5. Interim results of imposed and non-imposed PASS and results of non-imposed PASS submitted before the entry into force of the revised variations regulation[9]

7.5.1. Epoetin beta – **NEORECORMON** (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Valerie Strassmann (DE)

7.5.2. Epoetin theta – **BIOPOIN** (CAP), **EPORATIO** (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

[7] In accordance with Article 107p-q of Directive 2001/83/EC
[8] In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013
[9] In line with the revised variations regulation for any submission before 4 August 2013

7.5.3. Infliximab – REMICADE (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

7.5.4. Mannitol – BRONCHITOL (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

8. Renewals of the Marketing Authorisation, Conditional Renewals and Annual Reassessments

8.1.1. Abacavir – ZIAGEN (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

8.1.2. Clopidogrel – CLOPIDOGREL ACINO (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Maria Alexandra Pêgo (PT)

8.1.3. Clopidogrel – CLOPIDOGREL RATIOPHARM GMBH (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Maria Alexandra Pêgo (PT)

8.1.4. Clopidogrel –CLOPIDOGREL TEVA PHARMA (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Maria Alexandra Pêgo (PT)

8.1.5. Everolimus – AFINITOR (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

8.1.6. Lapatinib – TYVERB (CAP)

- PRAC consultation on a conditional renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

8.1.7. Mecasermin – INCRELEX (CAP)

- PRAC consultation on an annual reassessment of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Kirsti Villikka (FI)

8.1.8. Raltegravir – ISENTRESS (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

8.1.9. Repaglinide – REPAGLINIDE TEVA (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

8.1.10. Tocofersolan – VEDROP (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

8.1.11. Topotecan – TOPOTECAN ACTAVIS (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections

None

9.2. On-going or concluded pharmacovigilance inspection

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

10. Other Safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation (MA)

None

10.2. Timing and message content in relation to MS safety announcements

None

10.3. Timing and message content in relation to MS safety announcements

None

10.4. Other requests

None

11. Other Safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

11.1.1. **Cyproterone, ethinylestradiol** (NAP)

- PRAC consultation on a variation worksharing procedure, on Member State's request

***Status:** for discussion and agreement of advice to Member States*

Regulatory details:
Lead member: Menno van der Elst (NL)

11.2. Renewals of the Marketing Authorisation

None

11.3. Other requests

11.3.1. **Cefepime** (NAP)

- PRAC consultation on a PSUR worksharing procedure, on Member State's request

Status: *for discussion and agreement of advice to Member States*

Regulatory details:
Lead member: Margarida Guimarães (PT)

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

None

12.2. Pharmacovigilance audits and inspections

12.2.1. Pharmacovigilance Systems and their Quality Systems

None

12.2.2. Pharmacovigilance Inspections

12.2.2.1. Union Procedure on Follow-up to Pharmacovigilance Inspections

- Union procedure on the management of pharmacovigilance inspection findings with potential significant impact on the benefit-risk profile of the concerned medicinal products

Status*: for discussion*

12.2.3. Pharmacovigilance Audits

None

12.3. Periodic Safety Update Reports & Union Reference Date (EURD) List

12.3.1. Periodic Safety Update Reports

12.3.1.1. PSUR single assessment of substances contained in both centrally and nationally authorised products (PSUSA)

Status: *for discussion*

12.3.1.2. Revised PSUR Assessment Report template[10]

Status: *for adoption*

12.3.2. PSURs Repository

None

12.3.3. Union Reference Date (EURD) List

12.3.3.1. Consultation on the draft List, version January 2014

Status: *for discussion and agreement of the list*

12.4. Signal Management

12.4.1. Signal Management

- Feedback from Signal Management Review Technical (SMART) Working Group

Status: *for information*

- Consultation on flow charts and definitions for signal Management (SMART WS2)

Status: *for discussion*

12.5. Adverse Drug Reactions reporting and additional reporting

12.5.1. Management and Reporting of Adverse Reactions to Medicinal Products

None

12.5.2. Additional Monitoring

None

[10] Including RMP section (as applicable) in line with the revised variations regulation

12.5.3. List of Product under Additional Monitoring

12.5.3.1. Consultation on the draft List, version January 2014

Status: *for discussion*

12.6. EudraVigilance Database

12.6.1. Activities related to the confirmation of full functionality

None

12.6.2. Changes to EudraVigilance Database and functional specifications

None

12.7. Risk Management Plans and Effectiveness of risk Minimisations

12.7.1. Risk Management Systems

12.7.1.1. Progressive multifocal leukoencephalopathy (PML): possibilities for monitoring and labelling

- Development of an evidence-based strategy

Status: *for discussion*

12.7.2. Tools, Educational Materials and Effectiveness Measurement for Risk Minimisation

12.7.2.1. Publication of RMP summaries – process implementation

Status: *for information*

12.8. Post-authorisation Safety Studies

12.8.1. Post-Authorisation Safety Studies

None

12.9. Community Procedures

12.9.1. Referral Procedures for Safety Reasons

None

12.10. Risk communication and Transparency

12.10.1. Public Participation in Pharmacovigilance

None

12.10.2. Safety Communication

None

12.11. Continuous pharmacovigilance

12.11.1. Continuous Pharmacovigilance, Ongoing Benefit-Risk Evaluation, Regulatory Status and Planning of Public Communication

None

12.11.2. Incident Management

None

12.12. Interaction with EMA Committees and Working Parties

12.12.1. Paediatric Committee (PDCO)

- Concept paper on revision of the guideline on conduct of pharmacovigilance for medicines used by the paediatric population

Status: *for discussion*

12.12.2. Blood Products Working Party (BPWP)

- Intravenous immunoglobulins and haemolysis – Draft strategy

Status: *for discussion*

12.12.3. Healthcare Professionals Working Party (HCPWP)

- HCPWP draft work plan 2014

Status: *for adoption*

12.12.4. Patients' and Consumers' Working Party (PCWP)

- PCWP draft work plan 2014

Status: *for adoption*

12.12.5. Vaccine Working Party (VWP)

- Explanatory note on the withdrawal of the 'Note for Guidance on Harmonisation of Requirements for Influenza Vaccines' (CPMP/BWP/214/96) and of the Core SmPC/PIL for inactivated seasonal influenza vaccines (CMDh/128/2003/Rev5 and CMDh/129/2008/Rev3)

Status: *for discussion*

12.13. Interaction within the EU regulatory network

12.13.1. Pharmacovigilance Audit Facilitation Group (PAGF)

- Standardisation for preparing, performing and reporting pharmacovigilance audits to European Commission

***Status**: for discussion*

12.14. Contacts of the PRAC with external parties and interaction of the EMA with interested parties

12.14.1. Guidelines of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)

None

12.14.2. Innovative Medicines Initiative (IMI): Accelerated development of vaccine benefit-risk collaboration in Europe (ADVANCE) project

***Status**: for information*

12.14.3. Others

None

13. Any other business

13.1.1. EMA move in 2014 to new building

***Status**: for information*